Other News

BioSig Technologies, Inc. Partners with Summit Blue Capital to Provide Equipment Leasing Services

The leasing and finance program provides a non-recourse financial solution for PURE EP™ to improve purchase flexibility for U.S. hospitals Westport, CT, March 29, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve […]

ARTRYA OPENS US OPERATIONS IN LOS ANGELES

LOS ANGELES, March 29, 2022 /PRNewswire/ — Australian medical technology company, Artrya Limited, creator of the AI-based solution, Artrya Salix, that supports physicians in the diagnosis of coronary artery disease, today announces the formation of the Company’s American subsidiary, Artrya USA, Inc. (Artrya US) with its headquarters in Los Angeles, California. Ted Schwab and Jory Tremblay have been […]

Miracor Medical starts 2nd randomized study, targeting expanded indications. 300 patients have been treated with PiCSO®

AWANS, Belgium, March 29, 2022 /PRNewswire/ — Miracor Medical SA (Miracor Medical) today announced the first patient enrolled in the PICSO-AMI-V study to evaluate the benefits of PiCSO® (Pressure Controlled Intermittent Coronary Sinus Occlusion) therapy as an adjunct to conventional primary percutaneous coronary intervention (PCI) for patients presenting with inferior ST-Elevation Myocardial Infarction (STEMI). […]

Shimadzu Medical Systems USA installs Trinias unity edition at Cardiovascular Experts

TORRANCE, Calif., March 28, 2022 /PRNewswire/ — Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation is proud to announce the latest installation of a Trinias F12 unity edition (floor mounted cutting-edge angiography system) at Cardiovascular Experts Outpatient facility in Harrisburg, Pennsylvania.  The system was installed by Shimadzu’s dealer partner, Alpha Imaging (Willoughby, OH) […]

Einstein Researchers Find New Strategy for Preventing Clogged Arteries

BRONX, N.Y., March 28, 2022 /PRNewswire/ — Revving up a process that slows down as we age may protect against atherosclerosis, a major cause of heart attacks and strokes. In findings publishing online this week in Proceedings of the National Academy of Sciences (PNAS), scientists at Albert Einstein College of Medicine led by Ana Maria Cuervo, M.D., Ph.D., successfully […]

DIT Acquires Vascular Access Consultants in Austin, Texas

DALLAS, March 29, 2022 /PRNewswire/ — Dynamic Infusion Therapy, LLC (“DIT”), a market leading provider of outsourced vascular access services, has announced the acquisition of Vascular Access Consultants based in Austin, Texas.  Vascular Access Consultants has been providing expert services to healthcare facilities in Austin and the surrounding areas for the past 26 years under […]

Vascular Therapies Completes $25 Million Private Financing

– Proceeds to fund ACCESS 2 – a randomized clinical trial evaluating Sirogen™ for improving hemodialysis AV Fistula outcomes in high-risk patients – CRESSKILL, N.J., March 29, 2022 /PRNewswire/ — Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, today announced the closing […]

CareDx Partners with HeartBrothers Foundation to Help Patients Living with Heart Failure and Heart Transplant

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is partnering with the HeartBrothers Foundation as a corporate […]

Humacyte Reports Fourth Quarter and Year End 2021 Financial Results and Provides Business Update

— Advancing late-stage clinical and preclinical programs of the Human Acellular Vessel™ (HAV™) and other engineered tissues across several indications – — Multiple publications and scientific meeting presentations highlighting clinical and preclinical HAV results – — Conference call and live webcast at 8:00 am ET today – DURHAM, N.C., March […]

Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) Program

Further analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, explores the effect of KERENDIA® (finerenone) on cardiovascular (CV) and kidney outcomes in patients with chronic kidney disease associated with type 2 diabetes, with and without history of CV disease First Phase IIb PACIFIC trial, PACIFIC-AF, gathered information about […]